September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Efficacy of intravitreal aflibercept injection in eyes with diabetic macular edema
Author Affiliations & Notes
  • Norihiro Shimizu
    Chiba University Hospital, Funabashi, Chiba, Japan
  • Toshiyuki Oshitari
    Chiba University Hospital, Funabashi, Chiba, Japan
  • Tomoaki Tatsumi
    Chiba University Hospital, Funabashi, Chiba, Japan
  • Eiju Sato
    Chiba University Hospital, Funabashi, Chiba, Japan
  • Yoko Takatsuna
    Chiba University Hospital, Funabashi, Chiba, Japan
  • Shuichi Yamamoto
    Chiba University Hospital, Funabashi, Chiba, Japan
  • Footnotes
    Commercial Relationships   Norihiro Shimizu, None; Toshiyuki Oshitari, None; Tomoaki Tatsumi, None; Eiju Sato, None; Yoko Takatsuna, None; Shuichi Yamamoto, None
  • Footnotes
    Support  No
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2073. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Norihiro Shimizu, Toshiyuki Oshitari, Tomoaki Tatsumi, Eiju Sato, Yoko Takatsuna, Shuichi Yamamoto; Efficacy of intravitreal aflibercept injection in eyes with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2073.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Efficacy of intravitreal aflibercept injection in eyes with diabetic macular edema

Methods : The medical records of 46 eyes of 40 patients who were diagnosed with DME and had received IVA treatment in the Chiba University Hospital from December in 2014 to October in 2015 were reviewed. The IVA had been injected 3 times within 4 weeks and since then pro re nata. The CMT and BCVA were measured at 1, 3, and 6 months after the IVA. Of these 46 eyes, 36 had been treated with a sub-Tenon's injection of triamcinolone acetonide (STTA), 28 eyes with photocoagulation for microaneurysms, 30 eyes had panretinal photocoagulation, and 25 eyes had other types of anti-VEGF antibody injections (24 had ranibizumab and 1 had bevacizumab, and 1 had both of them).

Results : The mean age of the patients was 64.5 years, the mean injection times of IVA were 2.6 times for 6 months. The CMT was 481.5 μm before treatment, 368.6 μm at 1 month, 374.2 μm at 3 months, and 395.5 μm at 6 months after the IVA. The CMT was still significantly thinner at 6 months after the IVA (P<0.05). The mean BCVA in logMAR units was 0.39 before IVA, 0.34 at 1 month, 0.36 at 3 months, and 0.34 at 6 months after the IVA. The BCVA was significantly improved only at 1 and 6 months after the IVA (P<0.05). The CMT of eyes with serous retinal detachment (SRD) was still significantly thinner at 1 and 3 months, and the BCVA was significantly improved at 1 and 6 months after the IVA. In eyes without SRD, the CMT was significantly thinner throughout the entire period, and the BCVA was significantly improved at only 1 month after the IVA. In the eyes with previous IVR treatment, the CMT was significantly thinner during the observation period but the BCVA was not significantly improved at any time after the IVA. In the eyes without previous IVR treatment, the CMT was also significantly thinner during the observation period and the BCVA was significantly improved at only 6 months after the IVA.

Conclusions : The results indicate that IVA is effective until 6 months and is effective even in eyes with prior anti-VEGF antibody injection treatment.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×